Source: Web Search Revision Year: 2017 Publisher: Manufactured by Sanofi Egypt S.A.E under license from Sanofi-Aventis Germany
Novalgin 1 g solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection, nearly colourless to yellow. |
Novalgin 1 g solution for injection.
1 ml solution for injection contains 500 mg metamizole sodium.
Each vial with 2 ml solution for injection contains 1 g metamizole sodium.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Metamizole sodium |
Metamizole sodium is a pyrazolone derivative with analgesic, antipyretic and slight antiinflammatory and spasmolytic properties. It has the most potent analgesic effect of all the pyrazolone derivatives. As with other analgesics, its mechanism of action has not been elucidated in detail. It includes inhibition of prostaglandin synthesis (PGE1 and PGE2) and reversible inhibition of platelet aggregation. It inhibits cyclo-oxygenase and influences the effect of arachidonic acid. |
| List of Excipients |
|---|
|
Water for injection |
Novalgin 1 g solution for injection:
Brown, cylindrical glass vials supplied in packs of 5 × 2 ml and 10 × 2 ml and
hospital packs of 96 × 2 ml and 100 × 2 ml.
Brown, cylindrical glass vials supplied in packs of 4 × 5 ml, 6 × 5 ml and
hospital packs of 20 × 5 ml and 24 × 5 ml.
Not all pack sizes may be marketed.
Manufactured by Sanofi Egypt S.A.E under license from Sanofi-Aventis Germany
Novalgin 1 g solution for injection: 619647.00.03 : 619647.01.03
Date of first authorisation: 31 March 1998
Date of latest renewal: 07 August 2006
| Drug | Countries | |
|---|---|---|
| NOVALGIN | Austria, Germany, Turkey |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
